Marit Van Buuren

Company: BioNTech New!

Job title: Senior Director - Translational Cell Immunology

Seminars:

Clinical & Translational Learnings of BNT-221, a Neoantigen-Specific Adoptive T-Cell Therapy & Next Steps for Future Product Iterations 12:30 pm

An insight into NEO-STIM and its applications: our process to prime, activate and expand neoantigen specific T-cells An overview of clinical safety and efficacy results of BNT221 and deep characterization of the generated drug products and peripheral samples An outlook of what is next including process improvements and product enhancementsRead more

day: Conference Day One - Track B - AM